Bosutinib was approved by the FDA for the treatment of CML in 2012 because of its ability to inhibit the BCR/ABL fusion gene product and its anticancer effects, which have been observed in imatinib-resistant CML [214]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.